UBS Initiates Coverage of ALX Oncology with Buy Rating, Cites Pipeline Potential

UBS has launched coverage of ALX Oncology Inc. (ALXO) with a Buy rating, highlighting the company's clinical-stage oncology pipeline and strategic positioning in the immuno-oncology space. The move reflects growing analyst interest in mid-tier biotech firms advancing novel cancer therapies.

UBS analysts initiated coverage of ALX Oncology Inc. (ALXO) with a Buy rating, citing the company's advancing pipeline of investigational immuno-oncology agents, including ALX148, a bispecific antibody targeting PD-1 and LAG-3. The firm emphasized the potential for ALXO to capture market share in solid tumor indications where combination therapies are gaining traction. The rating follows a thorough evaluation of ALXO’s preclinical and early clinical data, which suggest favorable safety and pharmacodynamic profiles. The Buy rating is underpinned by a target price of $17.50 per share, representing approximately 45% upside from ALXO's closing price of $12.07 on March 6, 2026. This valuation assumes successful progression of ALX148 through Phase 2 trials, particularly in melanoma and non-small cell lung cancer (NSCLC), where key biomarkers indicate strong patient response potential. UBS also noted the company's lean operational structure and strategic partnerships with academic institutions that support its research and development efforts. The action impacts a small-cap biotech with a market cap of approximately $850 million as of early March 2026. While the Buy rating may attract incremental institutional interest, the stock remains volatile due to its stage of development and reliance on future trial outcomes. The broader healthcare sector, tracked by ETFs such as XLV and IEX, could see modest sector-specific flows if biotech sentiment improves, though ALXO’s influence remains limited due to its market size and liquidity profile.